DrugPatentWatch Database Preview
Drugs in Development Information for Ganitumab
Email this page to a colleague
» See Plans and PricingWhat is the development status for investigational drug Ganitumab?
Ganitumab is an investigational drug.
There have been 14 clinical trials for Ganitumab.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2014.
The most common disease conditions in clinical trials are Sarcoma, Neoplasm Metastasis, and Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Amgen, and NantCell, Inc.
There are eleven US patents protecting this investigational drug and two hundred and twenty-three international patents.
Summary for Ganitumab
| US Patents | 11 |
| International Patents | 223 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2014-12-01) |
| Vendors | 0 |
Recent Clinical Trials for Ganitumab
| Title | Sponsor | Phase |
|---|---|---|
| Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | National Cancer Institute (NCI) | Early Phase 1 |
| Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | M.D. Anderson Cancer Center | Early Phase 1 |
| Palbociclib + Ganitumab In Ewing Sarcoma | 1 Million 4 Anna Foundation | Phase 2 |
Clinical Trial Summary for Ganitumab
Top disease conditions for Ganitumab
Top clinical trial sponsors for Ganitumab
US Patents for Ganitumab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ganitumab | Start Trial | Multispecific constructs | AbbVie Stemcentrx LLC (North Chicago, IL) | Start Trial |
| Ganitumab | Start Trial | Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein | CureVac AG (Tubingen, DE) | Start Trial |
| Ganitumab | Start Trial | Binding-triggered transcriptional switches and methods of use thereof | The Regents of the University of California (Oakland, CA) | Start Trial |
| Ganitumab | Start Trial | P97 fragments with transfer activity | biOasis Technologies, Inc. (Vancouver, British Columbia, unknown) | Start Trial |
| Ganitumab | Start Trial | Meditopes and meditope-binding antibodies and uses thereof | City of Hope (Duarte, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ganitumab
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ganitumab | Canada | 2900764 | 2033-02-08 | Start Trial |
| Ganitumab | European Patent Office | 2954056 | 2033-02-08 | Start Trial |
| Ganitumab | Hong Kong | 1218930 | 2033-02-08 | Start Trial |
| Ganitumab | Japan | 2016509014 | 2033-02-08 | Start Trial |
| Ganitumab | World Intellectual Property Organization (WIPO) | 2014124326 | 2033-02-08 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
